ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.
Ryosuke OkamuraShumei KatoSuzanna LeeRebecca E JimenezJason K SicklickRazelle KurzrockPublished in: Journal for immunotherapy of cancer (2021)
Our findings suggest that ARID1A alterations merit further exploration as a novel biomarker correlating with better outcomes after checkpoint blockade immunotherapy.